DFP‐10825 is an RNAi therapeutic composed of TS shRNA conjugated with cationic liposomes that has downregulated TS in cancer xenograft models.11, 30 Accordingly, DFP‐10825 should be a feasible approach to control the malignancy of metastatic advanced gastric cancer and would meet the Japanese Gastric Cancer Treatment Guidelines. Here, TYMS is linked to cancer.